OncoMed Pharmaceuticals, Inc.
OMED
OMED was delisted on the 22nd of April, 2019.
68 hedge funds and large institutions have $179M invested in OncoMed Pharmaceuticals, Inc. in 2014 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 20 increasing their positions, 16 reducing their positions, and 9 closing their positions.
135% more call options, than puts
Call options by funds: $200K | Put options by funds: $85K
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
26% more capital invested
Capital invested by funds: $143M → $179M (+$36.5M)
25% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 16
10% more funds holding
Funds holding: 62 → 68 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Apex Capital
Orinda,
California
|
+$7.07M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$3.74M |
| 3 |
ICM
IronBridge Capital Management
Oakbrook Terrace,
Illinois
|
+$3.02M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$1.78M |
| 5 |
QI
QS Investors
New York
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIP
Convergence Investment Partners
Palm Beach Gardens,
Florida
|
-$2.12M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$1.97M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.84M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.68M |
| 5 |
VAM
Visium Asset Management
New York
|
-$1.42M |
OMED Hedge Fund Activity: Q4 2014 in Review
68 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in OncoMed Pharmaceuticals, Inc. (OMED) for Q4 2014, worth a combined $179M — up 26% from $143M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new OMED positions and 9 closed out — a net gain of 9 holders — while 20 added to existing stakes and 16 trimmed.
The largest buyer was Apex Capital, opening a new position worth an estimated $7.07M. The largest seller was Convergence Investment Partners, exiting entirely with an estimated $2.12M sold.
- 68 institutional investors held OncoMed Pharmaceuticals, Inc. (OMED) as of Q4 2014, up from 62 in Q3 2014.
- Funds reported $179M of OncoMed Pharmaceuticals, Inc. stock for Q4 2014, up 26% quarter-over-quarter.
- 18 funds opened new OncoMed Pharmaceuticals, Inc. positions in Q4 2014 and 9 closed out, a net change of +9 holders.
- The largest OncoMed Pharmaceuticals, Inc. buyer in Q4 2014 was Apex Capital, an estimated $7.07M added.
- The largest OncoMed Pharmaceuticals, Inc. seller in Q4 2014 was Convergence Investment Partners, an estimated $2.12M sold.
Based on aggregated 13F filings for Q4 2014.